hVIVO plc (LON:HVO – Get Free Report)’s stock price rose 10% during trading on Monday . The company traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). Approximately 7,804,669 shares changed hands during trading, an increase of 164% from the average daily volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Price Performance
The company has a market cap of £144.58 million, a price-to-earnings ratio of 708.33 and a beta of 0.97. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The business has a 50-day moving average price of GBX 20.25 and a 200 day moving average price of GBX 25.68.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Stories
- Five stocks we like better than hVIVO
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Sizing Up a New Opportunity for NVIDIA Investors
- What is the Australian Securities Exchange (ASX)
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- How to Capture the Benefits of Dividend Increases
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
